Overview

Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Status:
Completed

Trial end date:
2010-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the long-term efficacy and safety of vortioxetine, once daily (QD), in adults with major depressive disorder.

Phase:

Phase 3

Details

Lead Sponsor:

Takeda

Collaborator:

H. Lundbeck A/S

Treatments:

Vortioxetine